요로감염증 검사 시장 - 세계 예측(2026-2032년)

The Urinary Tract Infection Testing Market is projected to grow by USD 1.65 billion at a CAGR of 4.65% by 2032.

Urinary tract infection testing is becoming a critical component of modern diagnostics as health systems work to improve antimicrobial stewardship, reduce recurrent infections, and accelerate treatment decisions across primary care, emergency medicine, urology, obstetrics, pediatrics, and long-term care. UTIs remain among the most common bacterial infections worldwide, with a high clinical burden among women, older adults, pregnant patients, catheterized individuals, people with diabetes, and immunocompromised populations. Traditional urinalysis and urine culture continue to provide foundational evidence for diagnosis, while rapid dipstick testing, automated urine sediment analysis, mass spectrometry-enabled organism identification, molecular assays, antimicrobial susceptibility testing, and point-of-care platforms are reshaping how clinicians confirm infection and identify resistance. The executive priority is shifting from simple detection to clinically actionable urinary tract infection testing that supports faster diagnosis, targeted antibiotic use, reduced complications, and improved patient pathways.

Transformative Shifts in the Urinary Tract Infection Testing Landscape

The urinary tract infection testing landscape is undergoing a decisive transition from centralized, culture-dependent workflows toward faster, integrated, and patient-centric diagnostic models. Rising concern over antimicrobial resistance is increasing demand for tests that can distinguish bacterial infection from colonization, identify pathogens earlier, and support susceptibility-informed therapy. Clinical laboratories are adopting automation to improve throughput, standardize interpretation, and reduce turnaround time, while healthcare providers are expanding point-of-care urine testing in outpatient, urgent care, long-term care, and remote-care settings. Digital connectivity is also transforming reporting workflows by linking diagnostic results with electronic health records, clinical decision support, and antimicrobial stewardship programs. At the same time, regulatory expectations for analytical validity, clinical performance, quality management, and responsible test interpretation are strengthening, particularly for molecular urinary tract infection diagnostics. These shifts are positioning UTI testing as a strategic diagnostic category aligned with precision medicine, infection control, and value-based care.

Cumulative Impact of Artificial Intelligence on UTI Testing

Artificial intelligence is increasingly influencing urinary tract infection testing by improving image-based urine sediment analysis, automating microscopic review, supporting culture interpretation, and helping clinicians identify patients at risk of complicated or recurrent UTI. AI-enabled platforms can assist laboratories in triaging negative samples, flagging abnormal findings, reducing manual workload, and improving consistency in high-volume testing environments. In clinical care, machine learning models can combine urinalysis parameters, patient demographics, prior microbiology results, comorbidities, catheter status, pregnancy status, and prescribing history to support diagnostic confidence and antibiotic selection. The most meaningful impact is expected where AI is embedded into validated workflows rather than used as a standalone decision-maker. Data quality, demographic representativeness, cybersecurity, explainability, auditability, and clinical governance remain essential to safe adoption. When implemented responsibly, AI can help reduce unnecessary antibiotic prescribing, shorten time to targeted therapy, and enhance surveillance of resistance patterns in urinary tract pathogens.

Key Regional Insights Across Global UTI Testing Adoption

In Asia-Pacific, urinary tract infection testing demand is shaped by dense urban populations, expanding diagnostic infrastructure, high outpatient volumes, aging demographics, and growing attention to antimicrobial resistance surveillance in countries such as China, India, Japan, South Korea, and Australia. The region is seeing broader use of automated urinalysis, culture confirmation, and rapid testing as public and private providers work to improve access and laboratory efficiency. Europe benefits from established microbiology standards, stewardship-focused prescribing guidance, in vitro diagnostic oversight, and a strong emphasis on evidence-based use of urinalysis, urine culture, and susceptibility testing across primary and secondary care. North America is characterized by mature clinical laboratory networks, strong uptake of electronic health records, antimicrobial stewardship requirements, and increasing interest in molecular and point-of-care UTI diagnostics, particularly for recurrent, catheter-associated, and complicated infections. Latin America is advancing diagnostic access through hospital-based laboratories, public health programs, and private diagnostic networks, although variability in reimbursement, laboratory capacity, and rural access continues to influence testing pathways. Africa presents a dual reality: major unmet need for accessible UTI diagnostics alongside growing laboratory strengthening initiatives, where affordable point-of-care testing, antimicrobial resistance monitoring, and specimen referral systems are increasingly important for improving patient outcomes. The Middle East is investing in hospital modernization, digital healthcare, and advanced diagnostics, with UTI testing needs closely tied to diabetes prevalence, catheter-associated infections, expanding tertiary care services, and infection prevention priorities.

Key Group Insights for UTI Testing Priorities

NATO member countries, many of which overlap with advanced healthcare economies, place growing emphasis on resilient healthcare infrastructure, military and civilian infection surveillance, and standardized diagnostic readiness, reinforcing the importance of reliable urinary tract infection testing across routine, deployed, and high-acuity care settings. G7 countries generally show mature reimbursement structures, well-developed microbiology infrastructure, high digital health penetration, and strong adoption of automation, quality systems, and clinical decision support for UTI diagnosis. BRICS countries represent diverse but high-impact diagnostic environments, combining large patient populations, rising chronic disease burden, expanding laboratory networks, and increasing emphasis on affordable rapid testing that can support antibiotic optimization. The European Union is a leading policy environment for antimicrobial stewardship, in vitro diagnostic regulation, laboratory quality assurance, and cross-border resistance monitoring, creating strong demand for validated, clinically interpretable UTI testing methods. ASEAN countries are strengthening urinary tract infection testing capacity through expanding primary care access, hospital laboratory modernization, and regional efforts to address antimicrobial resistance, although diagnostic standardization and rural access remain uneven. GCC health systems are prioritizing advanced hospital diagnostics, digital health integration, and infection control, making rapid UTI testing and susceptibility-informed treatment relevant to tertiary care, outpatient settings, and chronic disease management.

Key Country Insights in Urinary Tract Infection Testing

China is rapidly expanding automated laboratory diagnostics and hospital-based molecular capabilities, driven by large patient volumes, urban hospital modernization, and national concern around antimicrobial resistance. The United States has a highly developed urinary tract infection testing ecosystem supported by extensive outpatient testing, hospital microbiology capacity, antimicrobial stewardship programs, electronic health record integration, and growing use of molecular diagnostics for complex cases. Japan has advanced laboratory automation, an aging population, and strong clinical emphasis on managing complicated infections in hospital and long-term care settings. India faces high UTI burden and significant variation in access to culture and susceptibility testing, making affordable rapid diagnostics, specimen quality improvement, and stewardship education especially important. Germany, the United Kingdom, France, Italy, and Spain demonstrate mature European testing environments where urinalysis, urine culture, susceptibility testing, and prescribing guidance are closely linked to stewardship objectives, laboratory accreditation, and quality standards. Australia combines robust microbiology infrastructure with stewardship-focused guidelines, while remote and regional access remains an important consideration for urine testing pathways. South Korea is characterized by advanced hospital laboratories, digital healthcare adoption, and focused management of complicated infections among older and hospitalized patients. Canada emphasizes evidence-based testing, stewardship, and equitable access across provincial healthcare systems, with particular focus on appropriate urine culture use and resistance monitoring. Russia maintains substantial hospital-based diagnostic capacity, with ongoing need for resistance surveillance and standardized testing access across a large geography. Brazil and Mexico are strengthening diagnostic access through public and private laboratory networks, while antibiotic resistance, variability in testing availability, and high primary care demand shape clinical practice.

Actionable Recommendations for UTI Testing Industry Leaders

Industry leaders should prioritize clinically validated urinary tract infection testing solutions that shorten time to actionable results while supporting antimicrobial stewardship. Investments should focus on rapid pathogen detection, susceptibility-informed workflows, automated urinalysis, laboratory information system connectivity, and decision support that helps clinicians avoid overtreatment of asymptomatic bacteriuria. Developers should generate strong clinical evidence across diverse patient groups, including older adults, pregnant patients, pediatric patients, catheterized patients, recurrent UTI populations, and regions with high antimicrobial resistance. Laboratories and providers should integrate testing algorithms that combine symptom assessment, urinalysis, culture confirmation, and resistance profiling based on clinical risk. Point-of-care solutions should be designed for usability, quality control, operator training, and result traceability, especially in primary care, urgent care, long-term care, and low-resource settings. Leaders should also build partnerships with healthcare systems to support training, diagnostic stewardship, data interoperability, and resistance surveillance without increasing inappropriate test utilization.

Research Methodology for Evidence-Based UTI Testing Insights

This executive summary is developed using a secondary research approach grounded in verified public health, clinical, regulatory, and scientific sources. The methodology includes review of peer-reviewed literature on urinary tract infection diagnosis, antimicrobial resistance, urinalysis, urine culture, rapid testing, molecular diagnostics, antimicrobial susceptibility testing, and point-of-care testing. It also considers guidance and surveillance perspectives from recognized health authorities, infection control bodies, laboratory medicine organizations, antimicrobial stewardship frameworks, and in vitro diagnostic regulatory references. Regional and country insights are synthesized from documented healthcare infrastructure trends, diagnostic access patterns, clinical practice environments, disease burden considerations, and regulatory factors. The analysis deliberately excludes market sizing, market estimation, market share, and forecasting, focusing instead on evidence-backed industry dynamics, clinical needs, technology adoption, and strategic implications. All insights are interpreted through the lens of diagnostic utility, patient outcomes, laboratory workflow, antimicrobial stewardship, and healthcare system readiness.

Conclusion on the Future of Urinary Tract Infection Testing

Urinary tract infection testing is evolving from routine urine screening into a strategically important diagnostic field that supports faster clinical decisions, improved antibiotic stewardship, and better management of complicated and recurrent infections. Automation, molecular diagnostics, point-of-care platforms, antimicrobial susceptibility testing, and artificial intelligence are improving the speed and consistency of UTI diagnosis, but their value depends on clinical validation, responsible interpretation, and integration with care pathways. Regional differences in laboratory capacity, reimbursement, stewardship maturity, regulatory readiness, and healthcare access will continue to shape adoption priorities. Organizations that align testing innovation with evidence-based clinical guidelines, interoperability, affordability, quality assurance, and resistance surveillance will be best positioned to meet rising diagnostic expectations while supporting safer, more targeted treatment for patients with suspected urinary tract infection.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary Tract Infection Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Automated Urinalysis
  • 7.2.1. Automated Microscopy
  • 7.2.2. Digital Imaging
  • 7.2.3. Flow Cytometry
• 7.3. Culture Test
• 7.4. Molecular Test
  • 7.4.1. Isothermal Amplification
  • 7.4.2. Next Generation Sequencing
  • 7.4.3. Pcr Assay
• 7.5. Rapid Test
  • 7.5.1. Dipstick Test
  • 7.5.2. Microscopy

8. Urinary Tract Infection Testing Market, by Technology

• 8.1. Introduction
• 8.2. Automated Systems
  • 8.2.1. Fully Automated
  • 8.2.2. Semi Automated
• 8.3. Culture Based
• 8.4. Immunoassays
  • 8.4.1. Chemiluminescent Immunoassay
  • 8.4.2. Elisa
  • 8.4.3. Lateral Flow Assay
• 8.5. Molecular Diagnostics
  • 8.5.1. Isothermal
  • 8.5.2. Next Generation Sequencing
  • 8.5.3. Pcr

9. Urinary Tract Infection Testing Market, by Sample Type

• 9.1. Introduction
• 9.2. Catheterized
• 9.3. Midstream Clean Catch
• 9.4. Suprapubic Aspiration

10. Urinary Tract Infection Testing Market, by Pathogen Type

• 10.1. Introduction
• 10.2. Bacterial UTI
• 10.3. Fungal UTI
• 10.4. Viral UTI

11. Urinary Tract Infection Testing Market, by Infection Type

• 11.1. Introduction
• 11.2. Lower Urinary Tract Infection
• 11.3. Upper Urinary Tract Infection
• 11.4. Complicated UTI
• 11.5. Uncomplicated UTI

12. Urinary Tract Infection Testing Market, by End User

• 12.1. Introduction
• 12.2. Clinics
• 12.3. Diagnostic Laboratories
• 12.4. Home Care
• 12.5. Hospitals

13. Urinary Tract Infection Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Urinary Tract Infection Testing Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Urinary Tract Infection Testing Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 77 Elektronika Kft.
• 17.2. Abbott Laboratories
• 17.3. Accelerate Diagnostics, Inc.
• 17.4. Acon Laboratories, Inc.
• 17.5. Arkray, Inc.
• 17.6. Becton, Dickinson and Company
• 17.7. Bio-Rad Laboratories, Inc.
• 17.8. Biocare Medical, LLC
• 17.9. bioMerieux SA
• 17.10. Cardinal Health, Inc.
• 17.11. Danaher Corporation
• 17.12. Dirui Industrial Co., Ltd.
• 17.13. EKF Diagnostics Holdings plc
• 17.14. F. Hoffmann-La Roche Ltd
• 17.15. Hologic, Inc.
• 17.16. Human Diagnostics Worldwide
• 17.17. Macherey-Nagel GmbH & Co. KG
• 17.18. Meridian Bioscience, Inc.
• 17.19. Mindray Medical International Limited
• 17.20. Nanosphere Health Sciences LLC
• 17.21. Nova Biomedical Corporation
• 17.22. QIAGEN N.V.
• 17.23. Randox Laboratories Ltd.
• 17.24. Sekisui Diagnostics, LLC
• 17.25. Siemens Healthineers AG
• 17.26. Sysmex Corporation
• 17.27. Thermo Fisher Scientific Inc.
• 17.28. Trivitron Healthcare